Phase II prospective randomized trial of weight loss prior to radical prostatectomy

Susanne M Henning; Colette Galet; Kiran Gollapudi; Joshua B Byrd; Pei Liang; Zhaoping Li; Tristan Grogan; David Elashoff; Clara E Magyar; Jonathan Said; Pinchas Cohen; William J Aronson

doi:10.1038/s41391-017-0001-1

Back

Phase II prospective randomized trial of weight loss prior to radical prostatectomy

Journal article

Open access

Peer reviewed

Phase II prospective randomized trial of weight loss prior to radical prostatectomy

Susanne M Henning, Colette Galet, Kiran Gollapudi, Joshua B Byrd, Pei Liang, Zhaoping Li, Tristan Grogan, David Elashoff, Clara E Magyar, Jonathan Said, …

Prostate cancer and prostatic diseases, Vol.21(2), pp.212-220

06/01/2018

DOI: 10.1038/s41391-017-0001-1

PMID: 29203893

Files and links (1)

url

https://doi.org/10.1038/s41391-017-0001-1View

Published (Version of record) Open Access

Abstract

Obesity is associated with poorly differentiated and advanced prostate cancer and increased mortality. In preclinical models, caloric restriction delays prostate cancer progression and prolongs survival. We sought to determine if weight loss (WL) in men with prostate cancer prior to radical prostatectomy affects tumor apoptosis and proliferation, and if WL effects other metabolic biomarkers. In this Phase II prospective trial, overweight and obese men scheduled for radical prostatectomy were randomized to a 5-8 week WL program consisting of standard structured energy-restricted meal plans (1200-1500 Kcal/day) and physical activity or to a control group. The primary endpoint was apoptotic index in the radical prostatectomy malignant epithelium. Secondary endpoints were proliferation (Ki67) in the radical prostatectomy tissue, body weight, body mass index (BMI), waist to hip ratio, body composition, and serum PSA, insulin, triglyceride, cholesterol, testosterone, estradiol, leptin, adiponectin, interleukin 6, interleukin 8, insulin-like growth factor 1, and IGF binding protein 1. In total 23 patients were randomized to the WL intervention and 21 patients to the control group. Subjects in the intervention group had significantly more weight loss (WL:-3.7 ± 0.5 kg; Control:-1.6 ± 0.5 kg; p = 0.007) than the control group and total fat mass was significantly reduced (WL:-2.1 ± 0.4; Control: 0.1 ± 0.3; p = 0.015). There was no significant difference in apoptotic or proliferation index between the groups. Among the other biomarkers, triglyceride, and insulin levels were significantly decreased in the WL compared with the control group. In summary, this short-term WL program prior to radical prostatectomy resulted in significantly more WL in the intervention vs. the control group and was accompanied by significant reductions in body fat mass, circulating triglycerides, and insulin. However, no significant changes were observed in malignant epithelium apoptosis or proliferation. Future studies should consider a longer term or more intensive weight loss intervention.

Apoptosis

Biomarkers - analysis

Body Mass Index

Caloric Restriction

Case-Control Studies

Cell Proliferation

Follow-Up Studies

Humans

Male

Middle Aged

Obesity - physiopathology

Overweight - physiopathology

Prognosis

Prospective Studies

Prostatectomy

Prostatic Neoplasms - metabolism

Prostatic Neoplasms - pathology

Prostatic Neoplasms - surgery

Weight Loss

Details

Title: Subtitle: Phase II prospective randomized trial of weight loss prior to radical prostatectomy
Creators: Susanne M Henning - University of California, Los Angeles
Colette Galet - University of California, Los Angeles
Kiran Gollapudi - University of California, Los Angeles
Joshua B Byrd - University of California, Los Angeles
Pei Liang - University of California, Los Angeles
Zhaoping Li - University of California, Los Angeles
Tristan Grogan - University of California, Los Angeles
David Elashoff - University of California, Los Angeles
Clara E Magyar - University of California, Los Angeles
Jonathan Said - University of California, Los Angeles
Pinchas Cohen - University of Southern California
William J Aronson - VA Greater Los Angeles Healthcare System
Resource Type: Journal article
Publication Details: Prostate cancer and prostatic diseases, Vol.21(2), pp.212-220
DOI: 10.1038/s41391-017-0001-1
PMID: 29203893
NLM abbreviation: Prostate Cancer Prostatic Dis
ISSN: 1365-7852
eISSN: 1476-5608
Grant note: P01 AG055369 / NIA NIH HHS P30 CA016042 / NCI NIH HHS P50 CA092131 / NCI NIH HHS UL1 TR001881 / NCATS NIH HHS
Language: English
Date published: 06/01/2018
Academic Unit: Injury Prevention Research Center; University of Iowa Health Care
Record Identifier: 9985137926802771

Metrics

1 Record Views